A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19
Status:
Completed
Trial end date:
2020-10-29
Target enrollment:
Participant gender:
Summary
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2
infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III
clinical study is aimed to assess the efficacy and safety of XC221 100 mg tablet, in COVID-19
patients during a 14-day treatment.
The primary objective of the study is to demonstrate the efficacy of XC221 100 mg tablet (200
mg daily dose) in achieving clinical improvement of COVID-19 symptoms.
The secondary objective of the study is to evaluate the safety of XC221 100 mg tablet (200 mg
daily dose) in COVID-19 patients.